Cargando…

Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen

BACKGROUND: Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Darko, Samuel Nkansah, Hanson, Henry, Twumasi-Ankrah, Sampson, Baffour-Awuah, Sandra, Adjei-Kusi, Priscilla, Yar, Denis, Owusu-Dabo, Ellis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204294/
https://www.ncbi.nlm.nih.gov/pubmed/32375658
http://dx.doi.org/10.1186/s12879-020-05053-z
_version_ 1783530034889228288
author Darko, Samuel Nkansah
Hanson, Henry
Twumasi-Ankrah, Sampson
Baffour-Awuah, Sandra
Adjei-Kusi, Priscilla
Yar, Denis
Owusu-Dabo, Ellis
author_facet Darko, Samuel Nkansah
Hanson, Henry
Twumasi-Ankrah, Sampson
Baffour-Awuah, Sandra
Adjei-Kusi, Priscilla
Yar, Denis
Owusu-Dabo, Ellis
author_sort Darko, Samuel Nkansah
collection PubMed
description BACKGROUND: Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of three monthly doses of 60 mg/kg/day PZQ on schistosome egg count, liver and renal function during the treatment of urinary schistosomiasis in Ghana. METHODS: A nested case-control study was designed from a cohort screened for schistosomiasis; 28 schistosomiasis positive cases by microscopy matched with 53 healthy controls by age and gender. The study population was urban dwellers from the Asokwa sub-metropolitan area, Kumasi in Ghana. Participants were within the age range of 6 to 30 years. We assessed Schistosoma haematobium egg counts in urine and its associated impact on liver and renal function at baseline, treatment and post-treatment phases using serum. RESULTS: Of the 28 cases and 53 controls, 78.6% and 81.1% were males respectively. Globulin levels before treatment was higher in cases [36.7 (32.8, 40.1) vrs 30.5 (22.4, 33.8), p = 0.005] at pre-treatment but not at post-treatment [35.8 (31.2, 39.1) vrs 37.4 (29.7, 43.0), p = 0.767]. Estimated cure rate was 42.9, 46.4 and 96.4% after first, second and third dose respectively. Schistosome egg counts dropped significantly (p = 0.001) from before second dose to post-treatment. Similarly, levels of alanine aminotransferase (p = 0.001), aspartate aminotransferase (p = 0.028) and gamma glutamyl transferase (p = 0.001) significantly declined towards post-treatment. Estimated glomerular filtration rate significantly improved from before second dose to post-treatment using both the Chronic Kidney Disease Epidemiology Program (p = 0.001) and 4-variable Modification of Diet in Renal Disease (p = 0.002) equations. CONCLUSION: Treatment of urinary Schistosoma hematobium infections with a repeated high monthly dose of 60 mg/kg of praziquantel for 3 months is safe and effective.
format Online
Article
Text
id pubmed-7204294
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72042942020-05-14 Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen Darko, Samuel Nkansah Hanson, Henry Twumasi-Ankrah, Sampson Baffour-Awuah, Sandra Adjei-Kusi, Priscilla Yar, Denis Owusu-Dabo, Ellis BMC Infect Dis Research Article BACKGROUND: Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of three monthly doses of 60 mg/kg/day PZQ on schistosome egg count, liver and renal function during the treatment of urinary schistosomiasis in Ghana. METHODS: A nested case-control study was designed from a cohort screened for schistosomiasis; 28 schistosomiasis positive cases by microscopy matched with 53 healthy controls by age and gender. The study population was urban dwellers from the Asokwa sub-metropolitan area, Kumasi in Ghana. Participants were within the age range of 6 to 30 years. We assessed Schistosoma haematobium egg counts in urine and its associated impact on liver and renal function at baseline, treatment and post-treatment phases using serum. RESULTS: Of the 28 cases and 53 controls, 78.6% and 81.1% were males respectively. Globulin levels before treatment was higher in cases [36.7 (32.8, 40.1) vrs 30.5 (22.4, 33.8), p = 0.005] at pre-treatment but not at post-treatment [35.8 (31.2, 39.1) vrs 37.4 (29.7, 43.0), p = 0.767]. Estimated cure rate was 42.9, 46.4 and 96.4% after first, second and third dose respectively. Schistosome egg counts dropped significantly (p = 0.001) from before second dose to post-treatment. Similarly, levels of alanine aminotransferase (p = 0.001), aspartate aminotransferase (p = 0.028) and gamma glutamyl transferase (p = 0.001) significantly declined towards post-treatment. Estimated glomerular filtration rate significantly improved from before second dose to post-treatment using both the Chronic Kidney Disease Epidemiology Program (p = 0.001) and 4-variable Modification of Diet in Renal Disease (p = 0.002) equations. CONCLUSION: Treatment of urinary Schistosoma hematobium infections with a repeated high monthly dose of 60 mg/kg of praziquantel for 3 months is safe and effective. BioMed Central 2020-05-06 /pmc/articles/PMC7204294/ /pubmed/32375658 http://dx.doi.org/10.1186/s12879-020-05053-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Darko, Samuel Nkansah
Hanson, Henry
Twumasi-Ankrah, Sampson
Baffour-Awuah, Sandra
Adjei-Kusi, Priscilla
Yar, Denis
Owusu-Dabo, Ellis
Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_full Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_fullStr Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_full_unstemmed Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_short Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
title_sort three monthly doses of 60 mg/kg praziquantel for schistosoma haematobium infection is a safe and effective treatment regimen
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204294/
https://www.ncbi.nlm.nih.gov/pubmed/32375658
http://dx.doi.org/10.1186/s12879-020-05053-z
work_keys_str_mv AT darkosamuelnkansah threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT hansonhenry threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT twumasiankrahsampson threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT baffourawuahsandra threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT adjeikusipriscilla threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT yardenis threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen
AT owusudaboellis threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen